Literature DB >> 15915474

Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction.

Kurt Benkestock1, Per-Olof Edlund, Johan Roeraade.   

Abstract

Most proteins in blood plasma bind ligands. Human serum albumin (HSA) is the main transport protein with a very high capacity for binding of endogenous and exogenous compounds in plasma. Many pharmacokinetic properties of a drug depend on the level of binding to plasma proteins. This work reports studies of noncovalent interactions by means of nanoelectrospray ionization mass spectrometry (nanoESI-MS) for determination of the specific binding of selected drug candidates to HSA. Warfarin, iopanoic acid and digitoxin were chosen as site-specific probes that bind to the main sites of HSA. Two drug candidates and two known binders to HSA were analyzed using a competitive approach. The drugs were incubated with the target protein followed by addition of site-specific probes, one at a time. The drug candidates showed predominant affinity to site I (warfarin site). Naproxen and glyburide showed affinity to both sites I and II. The advantages of nanoESI-MS for these studies are the sensitivity, the absence of labeled molecules and the short method development time. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915474     DOI: 10.1002/rcm.1967

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  9 in total

1.  A deconvolution method for the separation of specific versus nonspecific interactions in noncovalent protein-ligand complexes analyzed by ESI-FT-ICR mass spectrometry.

Authors:  Thorsten Daubenfeld; Anne-Pascale Bouin; Guillaume van der Rest
Journal:  J Am Soc Mass Spectrom       Date:  2006-06-21       Impact factor: 3.109

Review 2.  The role of the protein-binding on the mode of drug action as well the interactions with other drugs.

Authors:  Christine Tesseromatis; Anastasia Alevizou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

3.  Mass spectrometric strategies to improve the identification of Pt(II)-modification sites on peptides and proteins.

Authors:  Huilin Li; Jonathon R Snelling; Mark P Barrow; James H Scrivens; Peter J Sadler; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2014-05-21       Impact factor: 3.109

4.  Proteoform-Specific Protein Binding of Small Molecules in Complex Matrices.

Authors:  Geuncheol Gil; Pan Mao; Bharathi Avula; Zulfiqar Ali; Amar G Chittiboyina; Ikhlas A Khan; Larry A Walker; Daojing Wang
Journal:  ACS Chem Biol       Date:  2016-12-21       Impact factor: 5.100

5.  Measuring the NQO2: Melatonin Complex by Native Nano-Electrospray Ionization Mass Spectrometry.

Authors:  Jean A Boutin; Johann Stojko; Gilles Ferry; Sarah Cianferani
Journal:  Methods Mol Biol       Date:  2022

6.  Effect of tanshinone IIA on the noncovalent interaction between warfarin and human serum albumin studied by electrospray ionization mass spectrometry.

Authors:  Jie Liu; Xiaoru Wang; Zongwei Cai; Frank S C Lee
Journal:  J Am Soc Mass Spectrom       Date:  2008-06-28       Impact factor: 3.109

7.  Electrospray ionization mass spectrometry: a technique to access the information beyond the molecular weight of the analyte.

Authors:  Shibdas Banerjee; Shyamalava Mazumdar
Journal:  Int J Anal Chem       Date:  2011-12-15       Impact factor: 1.885

8.  Targeting the Endocannabinoid System for Neuroprotection: A 19F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA.

Authors:  Jianqin Zhuang; De-Ping Yang; Xiaoyu Tian; Spyros P Nikas; Rishi Sharma; Jason Jianxin Guo; Alexandros Makriyannis
Journal:  J Pharm Pharmacol (Los Angel)       Date:  2013

9.  Impact of germline and somatic missense variations on drug binding sites.

Authors:  C Yan; N Pattabiraman; J Goecks; P Lam; A Nayak; Y Pan; J Torcivia-Rodriguez; A Voskanian; Q Wan; R Mazumder
Journal:  Pharmacogenomics J       Date:  2016-01-26       Impact factor: 3.550

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.